Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Site-specific conjugation of native antibody

Site-specific conjugation of native antibody ABSTRACTTraditionally, non-specific chemical conjugations, such as acylation of amines on lysine or alkylation of thiols on cysteines, are widely used; however, they have several shortcomings. First, the lack of site-specificity results in heterogeneous products and irreproducible processes. Second, potential modifications near the complementarity-determining region may reduce binding affinity and specificity. Conversely, site-specific methods produce well-defined and more homogenous antibody conjugates, ensuring developability and clinical applications. Moreover, several recent side-by-side comparisons of site-specific and stochastic methods have demonstrated that site-specific approaches are more likely to achieve their desired properties and functions, such as increased plasma stability, less variability in dose-dependent studies (particularly at low concentrations), enhanced binding efficiency, as well as increased tumor uptake. Herein, we review several standard and practical site-specific bioconjugation methods for native antibodies, i.e., those without recombinant engineering. First, chemo-enzymatic techniques, namely transglutaminase (TGase)-mediated transamidation of a conserved glutamine residue and glycan remodeling of a conserved asparagine N-glycan (GlyCLICK), both in the Fc region. Second, chemical approaches such as selective reduction of disulfides (ThioBridge) and N-terminal amine modifications. Furthermore, we list site-specific antibody–drug conjugates in clinical trials along with the future perspectives of these site-specific methods. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Antibody Therapeutics Oxford University Press

Site-specific conjugation of native antibody

Download PDF
14 pages

Loading next page...
 
/lp/oxford-university-press/site-specific-conjugation-of-native-antibody-pjllqmtPAC
Publisher
Oxford University Press
Copyright
© The Author(s) 2020. Published by Oxford University Press on behalf of Antibody Therapeutics. All rights reserved. For Permissions, please email: journals.permissions@oup.com
eISSN
2516-4236
DOI
10.1093/abt/tbaa027
Publisher site
See Article on Publisher Site

Abstract

ABSTRACTTraditionally, non-specific chemical conjugations, such as acylation of amines on lysine or alkylation of thiols on cysteines, are widely used; however, they have several shortcomings. First, the lack of site-specificity results in heterogeneous products and irreproducible processes. Second, potential modifications near the complementarity-determining region may reduce binding affinity and specificity. Conversely, site-specific methods produce well-defined and more homogenous antibody conjugates, ensuring developability and clinical applications. Moreover, several recent side-by-side comparisons of site-specific and stochastic methods have demonstrated that site-specific approaches are more likely to achieve their desired properties and functions, such as increased plasma stability, less variability in dose-dependent studies (particularly at low concentrations), enhanced binding efficiency, as well as increased tumor uptake. Herein, we review several standard and practical site-specific bioconjugation methods for native antibodies, i.e., those without recombinant engineering. First, chemo-enzymatic techniques, namely transglutaminase (TGase)-mediated transamidation of a conserved glutamine residue and glycan remodeling of a conserved asparagine N-glycan (GlyCLICK), both in the Fc region. Second, chemical approaches such as selective reduction of disulfides (ThioBridge) and N-terminal amine modifications. Furthermore, we list site-specific antibody–drug conjugates in clinical trials along with the future perspectives of these site-specific methods.

Journal

Antibody Therapeutics – Oxford University Press

Published: Dec 18, 2020

Keywords: hybrid modality; bioconjugation; transglutaminase; glycan remodeling; antibody–drug conjugate (ADC)

References

  • Site-specific bioconjugation and convergent click chemistry enhances antibody-chromophore conjugate binding efficiency
    Sadiki, A; Kercher, EM; Lu, H
  • Strategies and challenges for the next generation of antibody-drug conjugates
    Beck, A; Goetsch, L; Dumontet, C
  • Antibody-drug conjugates: an emerging concept in cancer therapy
    Chari, RV; Miller, ML; Widdison, WC
  • Structural characterization of a monoclonal antibody-Maytansinoid Immunoconjugate
    Luo, Q; Chung, HH; Borths, C
  • Impact of ligand size and conjugation chemistry on the performance of universal chimeric antigen receptor T-cells for tumor killing
    Pellegrino, C; Favalli, N; Sandholzer, M
  • Site-specifically labeled (89)Zr-DFO-trastuzumab improves immuno-reactivity and tumor uptake for immuno-PET in a subcutaneous HER2-positive xenograft mouse model
    Kristensen, LK; Christensen, C; Jensen, MM
  • Site-specific conjugation of the indolinobenzodiazepine DGN549 to antibodies affords antibody-drug conjugates with an improved therapeutic index as compared with lysine conjugation
    Bai, C; Reid, EE; Wilhelm, A
  • Stability of protein pharmaceuticals: an update
    Manning, MC; Chou, DK; Murphy, BM
  • Protein isoaspartate methyltransferase-mediated 18O-labeling of isoaspartic acid for mass spectrometry analysis
    Liu, M; Cheetham, J; Cauchon, N
  • Arginine modifications by methylglyoxal: discovery in a recombinant monoclonal antibody and contribution to acidic species
    Chumsae, C; Gifford, K; Lian, W
  • Discovery of undefined protein cross-linking chemistry: a comprehensive methodology utilizing 18O-labeling and mass spectrometry
    Liu, M; Zhang, Z; Zang, T
  • Discovery of a chemical modification by citric acid in a recombinant monoclonal antibody
    Chumsae, C; Zhou, LL; Shen, Y
  • Detection and quantitation of succinimide in intact protein via hydrazine trapping and chemical derivatization
    Klaene, JJ; Ni, W; Alfaro, JF
  • When good intentions go awry: modification of a recombinant monoclonal antibody in chemically defined cell culture by Xylosone, an oxidative product of ascorbic acid
    Chumsae, C; Hossler, P; Raharimampionona, H
  • Discovery and characterization of a photo-oxidative histidine-histidine cross-link in IgG1 antibody utilizing (1)(8)O-labeling and mass spectrometry
    Liu, M; Zhang, Z; Cheetham, J
  • Mildly acidic conditions eliminate deamidation artifact during proteolysis: digestion with endoprotease Glu-C at pH 4.5
    Liu, S; Moulton, KR; Auclair, JR
  • Analysis of isoaspartic acid by selective proteolysis with Asp-N and electron transfer dissociation mass spectrometry
    Ni, W; Dai, S; Karger, BL
  • Detection of alkynes via click chemistry with a brominated coumarin azide by simultaneous fluorescence and isotopic signatures in mass spectrometry
    Yang, L; Chumsae, C; Kaplan, JB
  • Click chemistry: diverse chemical function from a few good reactions
    Kolb, HC; Finn, MG; Sharpless, KB
  • A stepwise huisgen cycloaddition process: copper(I)-catalyzed regioselective "ligation" of azides and terminal alkynes
    Rostovtsev, VV; Green, LG; Fokin, VV
  • A strain-promoted [3 + 2] azide-alkyne cycloaddition for covalent modification of biomolecules in living systems
    Agard, NJ; Prescher, JA; Bertozzi, CR
  • Single-site Labeling of native proteins enabled by a chemoselective and site-selective chemical technology
    Adusumalli, SR; Rawale, DG; Singh, U
  • Lysine bioconjugation on native albumin with a sulfonyl acrylate reagent
    Matos, MJ; Jimenez-Oses, G; Bernardes, GJL
  • Chemo- and regioselective lysine modification on native proteins
    Matos, MJ; Oliveira, BL; Martinez-Saez, N
  • AJICAP: affinity peptide mediated regiodivergent functionalization of native antibodies
    Yamada, K; Shikida, N; Shimbo, K
  • Site-specific antibody conjugation technology
  • Structure-guided engineering of a Pacific blue fluorophore ligase for specific protein imaging in living cells
    Cohen, JD; Thompson, S; Ting, AY
  • Site-specific protein modification using lipoic acid ligase and Bis-Aryl hydrazone formation
    Cohen, JD; Zou, P; Ting, AY
  • Use of microbial transglutaminase for the enzymatic biotinylation of antibodies
    Josten, A; Haalck, L; Spener, F
  • Modification of different IgG1 antibodies via glutamine and lysine using bacterial and human tissue transglutaminase
    Mindt, TL; Jungi, V; Wyss, S
  • Site-specific and stoichiometric modification of antibodies by bacterial transglutaminase
    Jeger, S; Zimmermann, K; Blanc, A
  • Probing the limits of Q-tag bioconjugation of antibodies
    Marculescu, C; Lakshminarayanan, A; Gault, J
  • Thiolation of Q295: site-specific conjugation of hydrophobic payloads without the need for genetic engineering
    Benjamin, SR; Jackson, CP; Fang, S
  • Substrate design enables heterobifunctional, dual "click" antibody modification via microbial transglutaminase
    Walker, JA; Bohn, JJ; Ledesma, F
  • Expanding the versatility of microbial transglutaminase using alpha-effect nucleophiles as noncanonical substrates
    Chio, TI; Demestichas, BR; Brems, BM
  • Dual site-specific antibody conjugates for sequential and orthogonal cargo release
    Thornlow, DN; Cox, EC; Walker, JA
  • Enzymatic conjugation using branched linkers for constructing homogeneous antibody-drug conjugates with high potency
    Anami, Y; Xiong, W; Gui, X
  • Transglutaminase-based chemo-enzymatic conjugation approach yields homogeneous antibody-drug conjugates
    Dennler, P; Chiotellis, A; Fischer, E
  • Recent progress in enzymatic protein labelling techniques and their applications
    Zhang, Y; Park, KY; Suazo, KF
  • Recent progress in transglutaminase-mediated assembly of antibody-drug conjugates
    Schneider, H; Deweid, L; Avrutina, O
  • DOTA-functionalized polylysine: a high number of DOTA chelates positively influences the biodistribution of enzymatic conjugated anti-tumor antibody chCE7agl
    Grunberg, J; Jeger, S; Sarko, D
  • Site-specific antibody conjugation strategy to functionalize virus-based nanoparticles
    Park, J; Chariou, PL; Steinmetz, NF
  • RN927C, a site-specific Trop-2 antibody-drug conjugate (ADC) with enhanced stability, is highly efficacious in preclinical solid tumor models
    Strop, P; Tran, TT; Dorywalska, M
  • A phase 1, dose-escalation study of PF-06664178, an anti-Trop-2/Aur0101 antibody-drug conjugate in patients with advanced or metastatic solid tumors
    King, GT; Eaton, KD; Beagle, BR
  • Mechanism of action of Guinea pig liver transglutaminase. I. Purification and properties of the enzyme: identification of a functional cysteine essential for activity
    Folk, JE; Cole, PW
  • Versatility of microbial transglutaminase
    Strop, P
  • Engineered, highly reactive substrates of microbial transglutaminase enable protein labeling within various secondary structure elements
    Rachel, NM; Quaglia, D; Levesque, E
  • Discovery of a microbial transglutaminase enabling highly site-specific labeling of proteins
    Steffen, W; Ko, FC; Patel, J
  • Local unfolding is required for the site-specific protein modification by transglutaminase
    Spolaore, B; Raboni, S; Ramos Molina, A
  • Biotechnological applications of transglutaminases
    Rachel, NM; Pelletier, JN
  • Site-specific reversible protein and peptide modification: transglutaminase-catalyzed glutamine conjugation and bioorthogonal light-mediated removal
    Moulton, KR; Sadiki, A; Koleva, BN
  • Purification and characteristics of a novel transglutaminase derived from microorganisms
    Ando, H; Adachi, M; Umeda, K
  • Microbial transglutaminase displays broad acyl-acceptor substrate specificity
    Gundersen, MT; Keillor, JW; Pelletier, JN
  • Substrate specificities of microbial transglutaminase for primary amines
    Ohtsuka, T; Sawa, A; Kawabata, R
  • Transglutaminase-catalyzed bioconjugation using one-pot metal-free bioorthogonal chemistry
    Rachel, NM; Toulouse, JL; Pelletier, JN
  • Transglutaminase-mediated PEGylation of proteins: direct identification of the sites of protein modification by mass spectrometry using a novel monodisperse PEG
    Mero, A; Spolaore, B; Veronese, FM
  • A new method to increase selectivity of transglutaminase mediated PEGylation of salmon calcitonin and human growth hormone
    Mero, A; Schiavon, M; Veronese, FM
  • Dual, site-specific modification of antibodies by using solid-phase immobilized microbial transglutaminase
    Spycher, PR; Amann, CA; Wehrmuller, JE
  • Covalent immobilisation of transglutaminase: stability and applications in protein PEGylation
    Grigoletto, A; Mero, A; Yoshioka, H
  • Enzyme-catalyzed transfer of a ketone group from an S-adenosylmethionine analogue: a tool for the functional analysis of methyltransferases
    Lee, BW; Sun, HG; Zang, T
  • Site-specific conjugation of native antibodies using engineered microbial transglutaminases
    Dickgiesser, S; Rieker, M; Mueller-Pompalla, D
  • Glycans of antibodies as a specific site for drug conjugation using glycosyltransferases
    Qasba, PK
  • The mechanistic impact of N-glycosylation on stability, pharmacokinetics, and immunogenicity of therapeutic proteins
    Zhou, Q; Qiu, H
  • Antibody conjugations via Glycosyl remodeling
    Toftevall, H; Nyhlen, H; Olsson, F
  • Site specific conjugation of fluoroprobes to the remodeled Fc N-glycans of monoclonal antibodies using mutant glycosyltransferases: application for cell surface antigen detection
    Boeggeman, E; Ramakrishnan, B; Pasek, M
  • Bioconjugation using mutant glycosyltransferases for the site-specific labeling of biomolecules with sugars carrying chemical handles
    Ramakrishnan, B; Boeggeman, E; Pasek, M
  • Glycan-mediated technology for obtaining homogeneous site-specific conjugated antibody-drug conjugates: synthesis and analytical characterization by using complementary middle-up LC/HRMS analysis
    Duivelshof, BL; Desligniere, E; Hernandez-Alba, O
  • Direct identification of nonreducing GlcNAc residues on N-glycans of glycoproteins using a novel chemoenzymatic method
    Boeggeman, E; Ramakrishnan, B; Kilgore, C
  • Applications of glycosyltransferases in the site-specific conjugation of biomolecules and the development of a targeted drug delivery system and contrast agents for MRI
    Ramakrishnan, B; Boeggeman, E; Qasba, PK
  • Preparation of well-defined antibody-drug conjugates through glycan remodeling and strain-promoted azide-alkyne cycloadditions
    Li, X; Fang, T; Boons, GJ
  • Site-specific antibody-drug conjugation through glycoengineering
    Zhou, Q; Stefano, JE; Manning, C
  • Site-specific antibody-drug conjugation through an engineered glycotransferase and a chemically reactive sugar
    Zhu, Z; Ramakrishnan, B; Li, J
  • Probing glycosyltransferase activities with the Staudinger ligation
    Hang, HC; Yu, C; Pratt, MR
  • Glycoengineering of human IgG1-Fc through combined yeast expression and in vitro chemoenzymatic glycosylation
    Wei, Y; Li, C; Huang, W
  • Straightforward glycoengineering approach to site-specific antibody-pyrrolobenzodiazepine conjugates
    Thompson, P; Ezeadi, E; Hutchinson, I
  • Chemoenzymatic conjugation of toxic payloads to the globally conserved N-glycan of native mAbs provides homogeneous and highly efficacious antibody-drug conjugates
    Geel, R; Wijdeven, MA; Heesbeen, R
  • Quantitative PET imaging of PD-L1 expression in xenograft and syngeneic tumour models using a site-specifically labelled PD-L1 antibody
    Christensen, C; Kristensen, LK; Alfsen, MZ
  • Enzyme-mediated methodology for the site-specific radiolabeling of antibodies based on catalyst-free click chemistry
    Zeglis, BM; Davis, CB; Aggeler, R
  • Glycoengineering of antibodies for modulating functions
    Wang, LX; Tong, X; Li, C
  • Bromopyridazinedione-mediated protein and peptide bioconjugation
    Chudasama, V; Smith, ME; Schumacher, FF
  • Homogeneous antibody-drug conjugates via site-selective disulfide bridging
    Forte, N; Chudasama, V; Baker, JR
  • Protein modification, bioconjugation, and disulfide bridging using bromomaleimides
    Smith, ME; Schumacher, FF; Ryan, CP
  • Recent chemical approaches for site-specific conjugation of native antibodies: technologies toward next-generation antibody-drug conjugates
    Yamada, K; Ito, Y
  • Next-generation disulfide stapling: reduction and functional re-bridging all in one
    Lee, MTW; Maruani, A; Baker, JR
  • Bridging disulfides for stable and defined antibody drug conjugates
    Badescu, G; Bryant, P; Bird, M
  • Reduction-alkylation strategies for the modification of specific monoclonal antibody disulfides
    Sun, MM; Beam, KS; Cerveny, CG
  • Desulfurization of cysteine-containing peptides resulting from sample preparation for protein characterization by mass spectrometry
    Wang, Z; Rejtar, T; Zhou, ZS
  • Bridging the conjugation gap: maintaining Disulfide bridges leads to improved homogeneity and stability for ADCs
    Godwin, A
  • Identifying unknown enzyme-substrate pairs from the cellular milieu with native mass spectrometry
    Catcott, KC; Yan, J; Qu, W
  • Capturing unknown substrates via in situ formation of tightly bound bisubstrate adducts: S-Adenosyl-vinthionine as a functional probe for AdoMet-dependent methyltransferases
    Qu, W; Catcott, KC; Zhang, K
  • Vinyl sulfonium as novel proteolytic enzyme inhibitor
    Zhao, G; Zhou, ZS
  • Where did the linker-payload go? A quantitative investigation on the destination of the released linker-payload from an antibody-drug conjugate with a maleimide linker in plasma
    Wei, C; Zhang, G; Clark, T
  • Site-specific PEGylation of protein disulfide bonds using a three-carbon bridge
    Balan, S; Choi, JW; Godwin, A
  • Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates
    Shen, BQ; Xu, K; Liu, L
  • Regioselective labeling of antibodies through N-terminal transamination
    Scheck, RA; Francis, MB
  • Targeting the N terminus for site-selective protein modification
    Rosen, CB; Francis, MB
  • Chemical mechanisms in biochemical reactions
    Schramm, VL
  • Site-specific PEGylation of human thyroid stimulating hormone to prolong duration of action
    Qiu, H; Boudanova, E; Park, A
  • Chemo-enzymatic detection of protein isoaspartate using protein isoaspartate methyltransferase and hydrazine trapping
    Alfaro, JF; Gillies, LA; Sun, HG
  • Site-specific protein bioconjugation via a pyridoxal 5'-phosphate-mediated N-terminal transamination reaction
    Witus, LS; Francis, M
  • One-step site-specific modification of native proteins with 2-pyridinecarboxyaldehydes
    MacDonald, JI; Munch, HK; Moore, T
  • N-terminal protein modification through a biomimetic transamination reaction
    Gilmore, JM; Scheck, RA; Esser-Kahn, AP
  • Chemical methods for the detection of protein N-homocysteinylation via selective reactions with aldehydes
    Zang, T; Dai, S; Chen, D
  • Site-specific protein transamination using N-methylpyridinium-4-carboxaldehyde
    Witus, LS; Netirojjanakul, C; Palla, KS
  • N-terminal alpha-amino group modification of antibodies using a site-selective click chemistry method
    Li, DZ; Han, BN; Wei, R
  • Formation of pyroglutamic acid from N-terminal glutamic acid in immunoglobulin gamma antibodies
    Chelius, D; Jing, K; Lueras, A
  • N-terminal glutamate to pyroglutamate conversion in vivo for human IgG2 antibodies
    Liu, YD; Goetze, AM; Bass, RB
  • In vitro characterization and stability profiles of antibody-fluorophore conjugates derived from interchain cysteine cross-linking or lysine bioconjugation
    Martin, C; Brachet, G; Colas, C
  • Enzymatic strategies for (near) clinical development of antibody-drug conjugates
    Berkel, SS; Delft, FL
  • First-in-human phase I study of anti-HER2 ADC MRG002 in patients with relapsed/refractory solid tumors
    Li, J; Guo, Y; Xue, J
  • Engineered thio-trastuzumab-DM1 conjugate with an improved therapeutic index to target human epidermal growth factor receptor 2-positive breast cancer
    Junutula, JR; Flagella, KM; Graham, RA
  • Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index
    Junutula, JR; Raab, H; Clark, S
  • Synthesis of site-specific antibody-drug conjugates using unnatural amino acids
    Axup, JY; Bajjuri, KM; Ritland, M
  • ARX788, a site-specific anti-HER2 antibody-drug conjugate, demonstrates potent and selective activity in HER2-low and T-DM1-resistant breast and gastric cancers
    Skidmore, L; Sakamuri, S; Knudsen, NA
  • Introducing genetically encoded aldehydes into proteins
    Carrico, IS; Carlson, BL; Bertozzi, CR
  • Exploring the effects of linker composition on site-specifically modified antibody-drug conjugates
    Albers, AE; Garofalo, AW; Drake, PM
  • Aldehyde tag coupled with HIPS chemistry enables the production of ADCs conjugated site-specifically to different antibody regions with distinct in vivo efficacy and PK outcomes
    Drake, PM; Albers, AE; Baker, J
  • Hydrolytically stable site-specific conjugation at the N-terminus of an engineered antibody
    Thompson, P; Bezabeh, B; Fleming, R
  • Peptide-cleavable self-immolative Maytansinoid antibody-drug conjugates designed to provide improved bystander killing
    Costoplus, JA; Veale, KH; Qiu, Q
  • A polymer-based antibody-Vinca drug conjugate platform: characterization and preclinical efficacy
    Yurkovetskiy, AV; Yin, M; Bodyak, N